Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been presented at the 2019 Society for Investigative Dermatology (SID) annual meeting in Chicago, USA. This clinical study is conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Initial results suggest that remetinostat gel offers a potentially effective and well-tolerated, non-surgical

Source: Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.